Septerna (NASDAQ:SEPN) Price Target Raised to $60.00

Septerna (NASDAQ:SEPN) had its price target boosted by equities research analysts at HC Wainwright from $40.00 to $60.00 in a report issued on Wednesday, MarketBeat Ratings reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 25.63% from the stock’s previous close.

Several other brokerages have also recently commented on SEPN. Raymond James Financial reiterated a “strong-buy” rating and issued a $49.00 price objective on shares of Septerna in a research note on Tuesday. Truist Financial lifted their price target on shares of Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research note on Friday, July 17th. Stifel Nicolaus set a $49.00 target price on shares of Septerna in a research note on Tuesday. Finally, Guggenheim boosted their price target on Septerna from $45.00 to $51.00 and gave the company a “buy” rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $49.00.

Septerna Stock Performance

SEPN opened at $47.76 on Wednesday. The business’s 50-day simple moving average is $34.94 and its 200-day simple moving average is $29.25. Septerna has a one year low of $10.62 and a one year high of $48.00. The stock has a market capitalization of $2.15 billion, a P/E ratio of -88.44 and a beta of 2.29.

Septerna (NASDAQ:SEPN) last announced its earnings results on Monday, August 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.14. The business had revenue of $26.75 million for the quarter, compared to analyst estimates of $19.22 million. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.59%. On average, equities research analysts forecast that Septerna will post -1.59 EPS for the current fiscal year.

Insider Activity

In other Septerna news, insider Samira Shaikhly sold 11,798 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $30.06, for a total transaction of $354,647.88. Following the transaction, the insider owned 793 shares of the company’s stock, valued at $23,837.58. This trade represents a 93.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Daniel D. Long sold 15,000 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $35.51, for a total transaction of $532,650.00. Following the sale, the senior vice president directly owned 96,412 shares of the company’s stock, valued at $3,423,590.12. This represents a 13.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 47,828 shares of company stock worth $1,584,314. Insiders own 5.80% of the company’s stock.

Institutional Investors Weigh In On Septerna

A number of institutional investors have recently added to or reduced their stakes in the company. Deutsche Bank AG grew its stake in Septerna by 5.3% during the fourth quarter. Deutsche Bank AG now owns 14,879 shares of the company’s stock worth $415,000 after buying an additional 744 shares during the period. Global Retirement Partners LLC acquired a new stake in Septerna in the 4th quarter valued at $35,000. JPMorgan Chase & Co. raised its position in Septerna by 15.0% in the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after purchasing an additional 1,315 shares during the period. PharVision Advisers LLC lifted its stake in shares of Septerna by 17.5% during the third quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock worth $224,000 after purchasing an additional 1,780 shares in the last quarter. Finally, Nuveen LLC boosted its position in shares of Septerna by 7.7% in the fourth quarter. Nuveen LLC now owns 25,798 shares of the company’s stock worth $719,000 after buying an additional 1,837 shares during the period.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.